Roche Holding AG (0QOK.IL)
IOB · CHF · Healthcare · Drug Manufacturers - General
CHF 323.90 (+0.00%) as of
Key statistics
- Market cap
- 274.85B
- P/E (TTM)
- 24.92
- EPS (TTM)
- 13.00
- Dividend yield
- 3.99%
- 52-week range
- 0.00 – 395.00
- Beta
- 0.18
- Revenue (TTM)
- 63.14B
- Profit margin
- 17.46%
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- Basel, Switzerland
- Employees
- 103,613
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.